FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

Stock Information for FSD Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.